DUBLIN--(BUSINESS WIRE)--The "Liquid Biopsy Market to 2027: Market Size, Trends and Growth Analysis" report has been added to ResearchAndMarkets.com's offering.
The global liquid biopsy market is expected to reach an estimated $10.4 billion by 2027 with a CAGR of 17.9% from 2022 to 2027.
The future of the global liquid biopsy market looks promising with opportunities in reference laboratories, hospitals and physician laboratories, and academic and research centers. The major drivers for this market are the increasing prevalence of cancer, preference for non-invasive procedures, and increasing need of early detection of high precision diseases in real time.
Emerging trends, which have a direct impact on the dynamics of the industry, include the usage of methylation-specific polymerase chain reaction (MS-PCR) liquid biopsy technology and the emergence of hybrid ctDNA and CTC target selector.
Therapy selection is the largest clinical application market, and circulating tumor DNA is the largest circulating biomarker segment. Growth in various segments of the liquid biopsy market are shown in the report.
Liquid Biopsy Market Insights
- The analyst forecasts circulating tumor DNA will remain the largest segment and is also expected to witness the highest growth over the forecast period due to increasing use of ctDNA biomarkers in next-generation sequencing (NGS) technologies for detecting diseases in real time and in early stage.
- Therapy selection will remain the largest clinical application over the forecast period due to its offerings of various benefits, such as non-invasiveness, access to tumor heterogeneity, real-time treatment monitoring, and recurrence detection in advance of significant tumor formation or metastasis.
- APAC will remain the fastest growing region over the forecast period due to rising non-invasive treatment, a rising incidence of cancer, and improving healthcare infrastructure.
List of Liquid Biopsy Companies
Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies, liquid biopsy companies cater to increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base.
Some of the liquid biopsy companies profiled in this report include-
- Guardant
- Bio-Rad Laboratories
- Qiagen
- MDxHealth
- Myriad Genetics
- Biocept
- Roche
- Illumina
- Thermofisher
Key Topics Covered:
1. Executive Summary
2. Global Liquid Biopsy Market Background and Classifications
2.1: Introduction, Background and Classification
2.2: Supply Chain
2.3: Industry Drivers and Challenges
3. Market Trends and Forecast Analysis from 2015 to 2026
3.1: Macroeconomic Trends and Forecasts
3.2: Global Liquid Biopsy Market Trends and Forecast
3.3: Global Liquid Biopsy Market by Product
3.3.1: Assay Kits
3.3.2: Instruments
3.3.3: Services
3.4: Global Liquid Biopsy Market by Circulating Biomarker
3.4.1: Circulating Tumor Cells (CTCs)
3.4.2: Circulating Tumor DNA (ctDNA)
3.4.3: Cell-Free DNA (cfDNA)
3.4.4: Extracellular Vesicles (EVs)
3.4.5: Other Circulating Biomarkers
3.5: Global Liquid Biopsy Market by Application
3.5.1: Oncology
3.5.1.1: Lung Cancer
3.5.1.2: Breast Cancer
3.5.1.3: Colorectal Cancer
3.5.1.4: Prostate Cancer
3.5.1.5: Liver Cancer
3.5.1.6: Other Cancer
3.5.2: Non-Cancer
3.6: Global Liquid Biopsy Market by Clinical Application
3.6.1: Early Cancer Screening
3.6.2: Therapy Selection
3.6.3: Treatment Monitoring
3.6.4: Recurrence Monitoring
3.7: Global Liquid Biopsy Market by End User
3.7.1: Reference Laboratories
3.7.2: Hospitals and Physician Laboratories
3.7.3: Academic and Research Centers
3.7.4: Other End Users
4. Market Trends and Forecast Analysis from 2015 to 2026
4.1: Global Liquid Biopsy Market by Region
4.2: North American Liquid Biopsy Market Trends and Forecast
4.2.1: North American Liquid Biopsy Market by Product
4.2.2: North American Liquid Biopsy Market by Circulating Biomarker
4.2.3: North American Liquid Biopsy Market by Application
4.2.4: North American Liquid Biopsy Market by Clinical Application
4.2.5: North American Liquid Biopsy Market by End Use
4.2.6: United States Liquid Biopsy Market
4.2.7: Canadian Liquid Biopsy Market
4.2.8: Mexican Liquid Biopsy Market
4.3: European Liquid Biopsy Market Trends and Forecast
4.4: APAC Liquid Biopsy Market Trends and Forecast
4.5: ROW Liquid Biopsy Market Trends and Forecast
5. Competitor Analysis
5.1: Product Portfolio Analysis
5.2: Market Share Analysis
5.3: Operational Integration
5.4: Geographical Reach
5.5: Porter's Five Forces Analysis
6. Growth Opportunities and Strategic Analysis
6.1: Growth Opportunity Analysis
6.1.1: Growth Opportunities for the Global Liquid Biopsy Market by Product
6.1.2: Growth Opportunities for the Global Liquid Biopsy Market by Circulating Biomarker
6.1.3: Growth Opportunities for the Global Liquid Biopsy Market by Application
6.1.4: Growth Opportunities for the Global Liquid Biopsy Market by Clinical Application
6.1.5: Growth Opportunities for the Global Liquid Biopsy Market by End Use
6.1.6: Growth Opportunities for the Global Liquid Biopsy Market by Region
6.2: Emerging Trends in the Global Liquid Biopsy Market
6.3: Strategic Analysis
6.3.1: New Product Development
6.3.2: Licensing and Certification
6.3.3: Mergers, Acquisitions, Joint Ventures, and Other Collaborations in the Global Liquid Biopsy Market
7. Company Profiles of Leading Players
- Bio-Rad Laboratories
- QIAGEN
- MDxHealth
- Myriad Genetics
- Biocept, Inc.
- F. Hoffmann-La Roche Ltd.
- Thermo Fisher Scientific Inc.
- Illumina, Inc.
- Cardiff Oncology
- Guardant Health
For more information about this report visit https://www.researchandmarkets.com/r/mkvivs
